PI3K p110 beta isoform inhibitors (AstraZeneca AB)

N/A

Report date: 2025/03/20 20:00:06
NME

Base Information

Drug NamePI3K p110 beta isoform inhibitors (AstraZeneca AB)
Drug Alias NameN/A
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionPhosphatidylinositol 3 kinase beta inhibitorsCoagulation factor inhibitors
TargetsCoagulation factorPhosphatidylinositol 3 kinase beta
Therapy Area/IndicationsThrombosis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySweden
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesAstrazeneca Ab
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesAstrazeneca Ab
Active IndicationsN/A
Inactive IndicationsThrombosis

Other Information

ATC CodeN/A
Related LinksN/A